4′-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation

[1]  J. Gertsch,et al.  A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  A. Poso,et al.  Robust Hydrolysis of Prostaglandin Glycerol Esters by Human Monoacylglycerol Lipase (MAGL) , 2014, Molecular Pharmacology.

[3]  V. Petrucci,et al.  One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors. , 2014, European journal of medicinal chemistry.

[4]  E. Sigel,et al.  Moderate concentrations of 4-O-methylhonokiol potentiate GABAA receptor currents stronger than honokiol. , 2014, Biochimica et biophysica acta.

[5]  A. Ultsch,et al.  R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice , 2014, Journal of Neuroimmunology.

[6]  V. Petrucci,et al.  Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. , 2014, ACS chemical biology.

[7]  J. Hong,et al.  Amelioration of Cognitive Dysfunction in APP/PS1 Double Transgenic Mice by Long-Term Treatment of 4-O-Methylhonokiol , 2014, Biomolecules & therapeutics.

[8]  S. Oh,et al.  Pharmacokinetics and Metabolism of 4‐O‐Methylhonokiol in Rats , 2014, Phytotherapy research : PTR.

[9]  V. Di Marzo,et al.  Prostamide F2α receptor antagonism combined with inhibition of FAAH may block the pro‐inflammatory mediators formed following selective FAAH inhibition , 2014, British journal of pharmacology.

[10]  Haoyue Sun,et al.  Δ9-THC-Caused Synaptic and Memory Impairments Are Mediated through COX-2 Signaling , 2013, Cell.

[11]  B. Jenkins,et al.  R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease , 2013, Brain Research.

[12]  C. Müller,et al.  The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists , 2013, PloS one.

[13]  Sachin Patel,et al.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation , 2013, Nature Neuroscience.

[14]  R. Capasso,et al.  Anandamide-derived Prostamide F2α Negatively Regulates Adipogenesis , 2013, The Journal of Biological Chemistry.

[15]  M. Cascio,et al.  Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors , 2013, British journal of pharmacology.

[16]  Y. Persidsky,et al.  Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation , 2013, Journal of Neuroimmune Pharmacology.

[17]  J. Gertsch,et al.  The antinociceptive triterpene β‐amyrin inhibits 2‐arachidonoylglycerol (2‐AG) hydrolysis without directly targeting cannabinoid receptors , 2012, British journal of pharmacology.

[18]  B. Lutz,et al.  Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors* , 2012, The Journal of Biological Chemistry.

[19]  A. Lichtman,et al.  Production and Actions of the Anandamide Metabolite Prostamide E2 in the Renal Medulla , 2012, Journal of Pharmacology and Experimental Therapeutics.

[20]  J. Gertsch,et al.  Evidence for Bidirectional Endocannabinoid Transport across Cell Membranes* , 2012, The Journal of Biological Chemistry.

[21]  J. Gertsch,et al.  Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors? , 2012, Journal of Neuroinflammation.

[22]  P. Anderle,et al.  Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. , 2012, Biochemical pharmacology.

[23]  M. Cascio,et al.  AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor , 2012, British journal of pharmacology.

[24]  A. Lichtman,et al.  Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability , 2012, PloS one.

[25]  S. Nam,et al.  Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models , 2012, Journal of Neuroinflammation.

[26]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[27]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[28]  A. Planas,et al.  Induction of COX-2 Enzyme and Down-regulation of COX-1 Expression by Lipopolysaccharide (LPS) Control Prostaglandin E2 Production in Astrocytes* , 2012, The Journal of Biological Chemistry.

[29]  A. Gowran,et al.  The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration , 2011, CNS neuroscience & therapeutics.

[30]  D. Nomura,et al.  Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.

[31]  L. Marnett,et al.  (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. , 2011, Nature chemical biology.

[32]  K. Mackie,et al.  COX‐2 and fatty acid amide hydrolase can regulate the time course of depolarization‐induced suppression of excitation , 2011, British journal of pharmacology.

[33]  J. Gertsch,et al.  Endocannabinoid content in fetal bovine sera - unexpected effects on mononuclear cells and osteoclastogenesis. , 2011, Journal of immunological methods.

[34]  K. Altmann,et al.  Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. , 2011, Chemistry & biology.

[35]  Jian Zhang,et al.  Inhibition of COX‐2 expression by endocannabinoid 2‐arachidonoylglycerol is mediated via PPAR‐γ , 2011, British Journal of Pharmacology.

[36]  S. Nam,et al.  Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx. , 2011, Journal of medicinal food.

[37]  H. Lee,et al.  4-O-methylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. , 2011, The Journal of nutritional biochemistry.

[38]  Yoichi Chiba,et al.  Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system , 2011, Brain Research.

[39]  Agnes L. Bodor,et al.  The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors , 2010, Nature Neuroscience.

[40]  Natasha T. Snider,et al.  Oxidation of the Endogenous Cannabinoid Arachidonoyl Ethanolamide by the Cytochrome P450 Monooxygenases: Physiological and Pharmacological Implications , 2010, Pharmacological Reviews.

[41]  C. Holmes,et al.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy , 2010, Alzheimers Res Ther.

[42]  D. Tulshian,et al.  Constitutive activity of cannabinoid‐2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242 , 2009, British journal of pharmacology.

[43]  R. Bauer,et al.  Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation. , 2009, Bioorganic & medicinal chemistry.

[44]  Benjamin F. Cravatt,et al.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects , 2008, Nature chemical biology.

[45]  S. Pettit,et al.  The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. , 2008, Pharmacology & therapeutics.

[46]  G. Sachs,et al.  Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes , 2008, British journal of pharmacology.

[47]  T. Kenakin.  Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.

[48]  T. Golde,et al.  Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice , 2007, BMC Neuroscience.

[49]  M. Glass,et al.  The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. , 2007, Current neuropharmacology.

[50]  J. Sullivan,et al.  In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? , 2006, British journal of pharmacology.

[51]  K. Mackie,et al.  The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  B. Alger,et al.  Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus , 2004, Nature Neuroscience.

[53]  B. Cravatt,et al.  Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry Published, JLR Papers in Press, January 16, 2004. DOI 10.1194/jlr.M300475-JLR200 , 2004, Journal of Lipid Research.

[54]  J. Morrow,et al.  Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and Ethanolamides* , 2002, The Journal of Biological Chemistry.

[55]  Rajnish A. Gupta,et al.  15-Lipoxygenase Metabolism of 2-Arachidonylglycerol , 2002, The Journal of Biological Chemistry.

[56]  アシュラフ・サエード,et al.  Peroxisome proliferator-activated receptor alpha agonist , 2001 .

[57]  J. Morrow,et al.  Metabolism of Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in Vivo * , 2001, The Journal of Biological Chemistry.

[58]  B. Kobilka,et al.  Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. , 2001, The Journal of pharmacology and experimental therapeutics.

[59]  F. Carroll,et al.  Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? , 2000, The Journal of pharmacology and experimental therapeutics.

[60]  P. Worley,et al.  COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[62]  J. Hong,et al.  Validation of cyclooxygenase-2 as a direct anti-inflammatory target of 4-O-methylhonokiol in zymosan-induced animal models , 2015, Archives of pharmacal research.

[63]  I. Ferrer,et al.  CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. , 2013, Journal of Alzheimer's disease : JAD.

[64]  S. Nam,et al.  4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of β-secretase activity. , 2012, Journal of Alzheimer's disease : JAD.

[65]  S. Korte,et al.  The amount of free corticosterone is increased during lipopolysaccharide-induced fever. , 2000, Life sciences.

[66]  K. Mackie,et al.  LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. , 1998, The Journal of pharmacology and experimental therapeutics.